Partner Headlines - EXEL

  1. Market Wrap For March 26: Markets Close Near Session Lows In ...

    Benzinga
  2. Mid-Afternoon Market Update: Markets Turn Red as Dish Network ...

    Benzinga
  3. Mid-Day Market Update: Five Below Jumps On Upbeat Results; Exelixis ...

    Benzinga
  4. Mid-Morning Market Update: Markets Open Higher; Francesca's Issues ...

    Benzinga
  5. Stocks Hitting 52-Week Lows

    Benzinga
  6. Morning Market Losers

    Benzinga
  7. Benzinga's Top #PreMarket Losers

    Benzinga
  8. Morning Market Movers

    Benzinga
  9. US Stock Futures Rise Ahead Of Housing Data

    Benzinga
  10. Exelixis Prices 10M Share Offering at $8 per Share

    Benzinga
  11. Oversold ETFs Looking Attractive (IHE, CSD, PSCE)

    Benzinga
  12. Exelixis Announces Promising Phase 1b Data for Cobimetinib in ...

    Benzinga
  13. US Stock Futures Rise Ahead Of Jobless Claims, GDP Data

    Benzinga
  14. Exelixis Announces Full Patient Enrollment for COMET-1 Phase ...

    Benzinga
  15. US Stock Futures Up After Upbeat China Data

    Benzinga
  16. Exelixis Initiates Phase 3 Clinical Trial of Cabozantinib

    Benzinga
  17. Exelixis Receives EMA Acceptance of Marketing Authorization App ...

    Benzinga
  18. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  19. Exel Presents Interim Data for Cabozantinib 40 mg Dose Cohort ...

    Benzinga
  20. First Solar, Sears Holdings Among Stocks Down on Above-average ...

    FoxBusiness
  21. Exelixis Says FDA Says NDA Has Been Removed from November Agenda

    Benzinga
  22. UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity ...

    Benzinga
  23. Social Media Outlook for Thursday August 9 (EAT, NOV, NWSA, FSYS)

    Benzinga
  24. Exelixis, Universal Display Corporation Among Stocks Up on High ...

    FoxBusiness
  25. FDA's Oncologic Drugs Advisory Committee to Review Exelixis New ...

    Benzinga
  26. Exelixis (EXEL) Loses 8.8% As Company Sells Stock, Debt

    MarketIntelligenceCenter
  27. Health Care Sector Wrap

    FoxBusiness
  28. HCA Holdings, American Capital Mortgage Investment Crp Among ...

    FoxBusiness
  29. Interpublic Group, Exelixis Gapping Down Monday

    FoxBusiness
  30. UPDATE: Exelixis Announces Proposed Convertible Debt Offering ...

    Benzinga
  31. Exelixis Proposed Offering 20M Shares

    Benzinga
  32. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  33. Social Media Outlook for Monday July 30 (SHAW, BBY, EXEL, VHC)

    Benzinga
  34. Benzinga's Top Pre-Market Gainers

    Benzinga
  35. FDA Grants Priority Review for Cabozantinib in Medullary Thyroid ...

    Benzinga
  36. Exelixis Announces Initiation of Cabozantinib Investigator-Sponsored ...

    Benzinga
  37. Jefferies Reiterates Hold Rating, $6 PT for Exelixis

    Benzinga
  38. Cabozantinib Demonstrates Durable Effects in Bone and Soft Tissue ...

    Benzinga
  39. Cabozantinib Meets Primary Endpoint of Progression Free Survival ...

    Benzinga
  40. Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily ...

    Benzinga
  41. Exelixis Completes Submission of New Drug Application for Cabozantinib ...

    Benzinga
  42. Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall Survival ...

    Benzinga
  43. Exelixis Expands the Cabozantinib Development Program Through ...

    Benzinga
  44. Exelixis Announces Initiation of Investigator-Sponsored Clinical ...

    Benzinga
  45. 5 Resilient Biotech Stocks to Buy for 2012

    GuruFocus
  46. Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest ...

    Benzinga
  47. Exelixis (EXEL) Gains 2.8% After Pricing 11 Million Share Offering ...

    MarketIntelligenceCenter
  48. Exelixis Announces Pricing of $60.5 Million Public Offering at ...

    Benzinga
  49. Exelixis Announces Proposed Public Offering of 10M Shares

    Benzinga
  50. Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data ...

    Benzinga
  51. Notable Call Options Activity on Exelixis

    Benzinga
  52. Exelixis Trading Higher After Licensing Agreement with Merck

    Benzinga
  53. Exelixis Lures Premium Sellers on Positive Drug Data

    SchaeffersResearch
Trading Center